(firstQuint)L19TNF in Combination With Doxorubicin in Patients With Advanced Solid Tumours.

 In the clinical trial 3-6 patients will be assigned to L19TNFalfa at one of the following sequential dose levels (10.

4 mu g/kg, 13 mu g/kg and 17 mu g/kg) in combination with a fixed dose of doxorubicin.

 The RD will be defined following a traditional 3+3 design.

 The dose escalation will continue until the MTD is found, that is until at least two patients among a cohort of three to six patients experience a dose limiting toxicity (DLT).

.

 L19TNF in Combination With Doxorubicin in Patients With Advanced Solid Tumours@highlight

Prospective, open-label, non randomized, dose escalation study that will be conducted in sequential cohorts of patients.

